Roche expands access to HPV testing on cobas 5800 molecular system

Nov. 7, 2023
The cobas HPV test has been approved by the FDA for use on the company’s newly launched, compact and fully automated cobas 5800 molecular instrument.

Roche announced the recent U.S. Food and Drug Administration (FDA) approval of the cobas HPV test for use on its next-generation cobas 5800 molecular instrument.

The cobas HPV test is indicated for use for routine cervical-cancer screening as per professional medical guidelines, including triage of ASC-US cytology, co-testing (or adjunctive screen) with cytology, and HPV primary screening of women to assess the risk for cervical precancer and cancer. The cobas 5800 supports loading primary-collection vials directly onto the compact system, minimizing hands-on time.

Roche release